Gritstone Oncology Inc. Stock News

NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advise

The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars a

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago.

A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will

Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 million contract with BARDA to conduct a phase 2b

With the extreme volatility in today's stock market, gaining an edge requires more than just a list of penny stocks to watch. Investors need to leverage the right tools and resources.

EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced t

EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th

Gritstone bio, Inc. (NASDAQ:GRTS ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 AM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Al

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.34 per share a year ago.

Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point.

Gritstone bio Inc. (NASDAQ:GRTS ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Al